Bone Turnover

Biomarker

Related News

Breast Cancer Treatment Side Effects: Cardiotoxicity and Bone Health Challenges

Mar 13, 2026

Recent studies examine self-management strategies for breast cancer treatment-related cardiotoxicity and highlight risks of vertebral fractures after discontinuing denosumab therapy in patients receiving aromatase inhibitors.

FDA Approves Denosumab Biosimilars and Issues Hypocalcemia Safety Guidance

Dec 22, 2025

The FDA approved multiple denosumab biosimilars in late 2025 and issued REMS safety updates emphasizing severe hypocalcemia risk in patients with advanced chronic kidney disease, including reported hospitalizations and fatalities.